Emoclot 500iu/10ml Human Plasma Coagulation Factor VIII Infusion In Pakistan

Emoclot 500iu/10ml Human Plasma Coagulation Factor VIII Infusion In Pakistan

Emoclot 500 IU/10 ml is a human plasma-derived coagulation factor VIII medicine used to treat and help prevent bleeding in patients with Hemophilia A, a condition in which the blood does not clot properly due to a deficiency of factor VIII.

It replaces the missing clotting factor, helping the body form blood clots and control bleeding. It may also be used in selected cases of acquired factor VIII deficiency under specialist supervision.

Emoclot is supplied as a powder with a solvent for preparation before administration. It must be prescribed and administered under the supervision of a healthcare professional experienced in treating bleeding disorders.

Key Benefits

• Bleeding Control: Helps control bleeding episodes associated with factor VIII deficiency.

• Hemophilia A Management: Replaces deficient clotting factor VIII in patients with Hemophilia A.

• Bleeding Prevention: May be used to prevent bleeding when prescribed as part of an individual treatment plan.

• Clotting Support: Helps restore the blood's ability to form clots.

• Specialist Treatment: Supports individualized management of certain inherited or acquired bleeding disorders.

Effectiveness depends on the patient's condition, severity of bleeding, and response to treatment.

Ingredients

• Active Ingredient: Human plasma-derived coagulation factor VIII.

• Strength: 500 IU per vial.

• Concentration After Reconstitution: Approximately 50 IU/ml in 10 ml.

• Other Ingredients: Sodium chloride, trisodium citrate, glycine, and calcium chloride.

• Solvent: Water for injections.

• Additional Protein: The preparation contains human von Willebrand factor.

   

Specifications

How to Use

1. Emoclot should be prepared and administered by a qualified healthcare professional following the official product instructions.

2. The powder must be reconstituted using the supplied solvent and appropriate sterile equipment.

3. It is administered intravenously, with the rate determined by the treating healthcare professional.

4. The dose and frequency depend on body weight, factor VIII levels, the location and severity of bleeding, and the treatment objective.

5. Factor VIII levels and clinical response may need monitoring during treatment.

6. Do not mix Emoclot with other medicines unless compatibility has been specifically established.